Hepatitis C treatment: an incipient therapeutic revolution

被引：43

作者：

deLemos, Andrew S. ^{[1
]}

Chung, Raymond T. ^{[2
,3
]}

机构：

[1] Carolinas Med Ctr, Ctr Liver Dis & Transplantat, Dept Med, Charlotte, NC 28203 USA

[2] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Liver Ctr, Boston, MA 02114 USA

[3] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Div, Boston, MA 02114 USA

来源：

TRENDS IN MOLECULAR MEDICINE | 2014年 / 20卷 / 06期

关键词：

hepatitis C; pegylated interferon; NS3-4A serine protease inhibitors; direct-acting antivirals (DAAs); sofosbuvir; simeprevir; HCV GENOTYPE 1; TREATMENT-NAIVE PATIENTS; PHASE-III TRIAL; SOFOSBUVIR PLUS RIBAVIRIN; TREATMENT-EXPERIENCED PATIENTS; PEGYLATED INTERFERON ALPHA-2A; GENOME-WIDE ASSOCIATION; VIRUS-INFECTION; SIMEPREVIR TMC435; GENETIC-VARIATION;

D O I：

10.1016/j.molmed.2014.02.002

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

An exciting paradigm shift is occurring in the treatment of hepatitis C virus (HCV). We now have the capacity to specifically target therapy to HCV proteins, and thereby directly interrupt the viral life cycle. The first direct-acting antivirals (DAAs), the NS3-4A serine protease inhibitors boceprevir and telaprevir, improved the rate of sustained virologic response (SVR), but their toxicities combined with PEG-IFN and RBV limited their overall efficacy. Sofosbuvir, a nucleotide HCV polymerase inhibitor, is now available and offers better tolerability and efficacy across all HCV genotypes. The next phase of therapy will be combining several classes of DAAs without IFN in order to make sustained clearance of hepatitis C deliverable to a much larger number of infected individuals.

引用

页码：315 / 321

页数：7

共 45 条

[1] The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 [J].

Armstrong, Gregory L. ;

Wasley, Annemarie ;

Simard, Edgar P. ;

McQuillan, Geraldine M. ;

Kuhnert, Wendi L. ;

Alter, Miriam J. .

ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) :705-714

[2]

Chayama K, 2013, HEPATOLOGY, V58, p313A

[3]

Curry MP, 2013, HEPATOLOGY, V58, p314A

[4] Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression [J].

Davis, Gary L. ;

Alter, Miriam J. ;

El-Serag, Hashem ;

Poynard, Thierry ;

Jennings, Linda W. .

GASTROENTEROLOGY, 2010, 138 (02) :513-U141

[5] Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection [J].

Everson, Gregory T. ;

Sims, Karen D. ;

Rodriguez-Torres, Maribel ;

Hezode, Christophe ;

Lawitz, Eric ;

Bourliere, Marc ;

Loustaud-Ratti, Veronique ;

Rustgi, Vinod ;

Schwartz, Howard ;

Tatum, Harvey ;

Marcellin, Patrick ;

Pol, Stanislas ;

Thuluvath, Paul J. ;

Eley, Timothy ;

Wang, Xiaodong ;

Huang, Shu-Pang ;

McPhee, Fiona ;

Wind-Rotolo, Megan ;

Chung, Ellen ;

Pasquinelli, Claudio ;

Grasela, Dennis M. ;

Gardiner, David F. .

GASTROENTEROLOGY, 2014, 146 (02) :420-429

[6] Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C [J].

Fontana, R. J. ;

Hughes, E. A. ;

Bifano, M. ;

Appelman, H. ;

Dimitrova, D. ;

Hindes, R. ;

Symonds, W. T. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (06) :1601-1605

[7] Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation [J].

Fontana, Robert J. ;

Hughes, Eric A. ;

Appelman, Henry ;

Hindes, Robert ;

Dimitrova, Dessislava ;

Bifano, Marc .

LIVER TRANSPLANTATION, 2012, 18 (09) :1053-1059

[8]

Forns X, 2013, HEPATOLOGY, V58, p737A

[9] HCV-TARGET: A LONGITUDINAL, OBSERVATIONAL STUDY OF NORTH AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (HCV) TREATED WITH BOCEPREVIR OR TELAPREVIR [J].

Fried, M. W. ;

Reddy, K. R. ;

Di Bisceglie, A. M. ;

Jensen, D. M. ;

Jacobson, J. M. ;

Sulkowski, M. S. ;

Terrault, N. A. ;

Afdhal, N. H. ;

Gordon, S. C. ;

Pockros, P. J. ;

Kwo, P. Y. ;

Everson, G. T. ;

Sherman, K. E. ;

Muir, A. J. ;

Pearlman, B. L. ;

Stewart, T. G. ;

Vainorius, M. ;

Peter, J. A. ;

Nelson, D. R. .

JOURNAL OF HEPATOLOGY, 2013, 58 :S335-S335

[10] Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C [J].

Gane, Edward J. ;

Stedman, Catherine A. ;

Hyland, Robert H. ;

Ding, Xiao ;

Svarovskaia, Evguenia ;

Symonds, William T. ;

Hindes, Robert G. ;

Berrey, M. Michelle .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (01) :34-44

← 1 2 3 4 5 →